Drugs / 90Y-DOTATOC
90Y-DOTATOC
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03724409 | Oct 2018 → Mar 2021 | neuroendocrine neoplasm | Sandeep Laroia | Terminated | No outcome recorded |
| Phase 0 | NCT03197012 | Jul 2017 → May 2019 | neuroendocrine neoplasm | Thomas Hope | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04296149 | Feb 2017 → Dec 2018 | digestive system neuroendocrine neoplasm | European Institute of Oncology | Completed | No outcome recorded |
| Phase 2 | NCT02488512 | Dec 2016 → Feb 2018 | diffuse large B-cell lymphoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00696930 | Jun 2008 | carcinoid tumor | Molecular Insight Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [90]Y-DOTATOC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03724409 ↗ |
| Known as | 90Y-SMT487 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00696930 ↗ |
| Known as | Y90-DOTA-Tyr3-Octreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04296149 ↗ |
| Modality | Peptide | “PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS.” NCT02488512 ↗ |
| Route | Intravenous | “The 90Y-DOTATOC will be slowly infused intravenously.” NCT02488512 ↗ |